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Gene therapy and solid-organ transplantation. Recent develop- absence of immunosuppressive treatment, (2) the preven-
ments in transplantation medicine improved the short- and tion of nonimmunologic causes of graft loss, such as ische-
long-term survival of solid-organ transplantation. However, mia-reperfusion injury and arteriosclerosis, and (3) xeno-chronic allograft rejection, the side effects of the long-term
transplantation as a potential solution for organ shortage.immunosuppressive treatment, and organ shortage are still the
Gene therapy has the potential to meet these chal-major obstacles to achieving long-term survival. Gene therapy
has the potential to meet these challenges and has unique lenges and has unique advantages in transplantation.
advantages in transplantation. In this review we summarize Allotransplantation requires the removal of tissues from
the studies using gene therapy in solid-organ transplantation.
one individual and offers the possibility of treating cells
or organs ex vivo with gene transfer vectors prior to
implantation, thus avoiding many of the hurdles encoun-
The introduction of new immunosuppressive medica- tered with in vivo gene transfer. This gives the advantage
tions significantly increased the short-term and long-term of local production of immunosuppressive molecules,
survival of kidney grafts from both living and cadaver
without exposing the recipient to the systemic side-
donors. The projected half-life of cadaver transplanta-
effects of the drugs and may potentially achieve antigen
tion was increased to 13.8 years, and living-related trans-
specific immunosuppression. Higher concentrations of
plantation was increased to 21.6 years in 1995. Despite
vector can be administered to organs ex vivo or cells in
the reduction of the rate of acute rejection, it is still one
vitro, and excess vector washed away, decreasing chancesof the major obstacles to achieving long-term survival.
for toxicity, immunogenecity, and systemic transductionThe projected half-life of cadaver transplants with an
or expression of the vector. One of the major limitationsepisode of acute rejection was only increased to 8.8 years
to the gene therapy is that gene expression and proteinfrom 7.0 years [1]. Chronic rejection remains the most
production are transient, which significantly limits theimportant cause of graft loss in long-term studies, and
ability of gene transfer techniques for the treatment ofacute rejection is the major predictor of chronic rejec-
inborn errors of metabolism, genetic deficiencies, ortion. Death with graft function is increasingly becoming
chronic disease. However, in the setting of transplanta-an important cause of graft loss, occurring in 10 to 40%
tion, transient gene expression may be sufficient for im-of transplanted patients, due to long-term immunosup-
mune modulation or even desirable because the poten-pressive treatment in particular the increased risk of in-
tial toxicities and adverse effects of prolonged vectorfection, malignancy, and cardiovascular disease [2]. De-
persistence and expression or immunosuppressive mole-layed graft function is another independent risk factor
cule production could be avoided [4].for long-term survival [3]. Another hurdle in transplanta-
Gene therapy can be used for the transfer of gene thattion is the increasing number of patients on a waiting
induces secreted proteins [such as interleukin-10 (IL-10),list because of organ shortage, limiting the opportunities
transforming growth factor- (TGF-)], overexpressionfor transplantation. To overcome these obstacles, three
of membrane-bound molecules (such as Fas ligand) ormain research areas in the field of transplantation have in-
intracellular proteins (such as antiapoptotic molecules).creased interest: (1) the prevention of acute and chronic
In this review, we summarize the studies using generejection with new immunotherapies with less systemic
therapy in solid-organ transplantation.immunosuppression and preferably that induce trans-
plantation tolerance, as defined by graft acceptance in the
IMMUNOMODULATION
The alloimmune response is a T-cell-dependent pro-Key words: transplantation, rejection, allograft, gene therapy, xeno-
transplantation. cess that involves the orchestration of different amplifi-
cation and effector mechanisms, including natural killer 2002 by the International Society of Nephrology
S-56
Akalin and Bromberg: Gene therapy and transplantation S-57
cells, B cells, macrophages, cytokines, and chemokines. studied in the context of the Th1/Th2 paradigm. This
paradigm proposes that Th1-derived cytokines (IL-2,T cell recognizes the antigenic peptides in the groove of
major histocompatibility complex (MHC) molecules on interferon ) promote allograft rejection by mediating
delayed-type hypersensitivity reactions, cytotoxic T-lym-the surface of antigen-presenting cells (APCs). This so-
called signal 1 delivers intracellular signals and confers phocyte generation, and macrophage activation and that
Th2-derived cytokines (IL-4 and IL-10) protect rejectionantigen specificity to the immune response but alone is
insufficient for full T-cell activation. The second signal, by down-regulating immune responses. Previous studies
in rat transplantation models showed that the inductionor “costimulatory signal,” is provided by interactions be-
tween specific receptors on the T cells, CD28, CTLA4 of tolerance in some studies is associated with the inhibi-
tion of Th1 cytokines and the sparing Th2 cytokines [15].(CD152), CD40 ligand, and their respective ligands on
APCs, B7-1 (CD80), B7-2 (CD86), and CD40. Block- TGF- can also suppress T-cell, B-cell, neutrophil, and
inflammatory cytokine functions. Many studies have in-ing the costimulatory signals with the fusion protein
CTLA4Ig and/or anti-CD40 ligand antibodies results in vestigated the role of these immunomodulatory cyto-
kines by using gene therapy. IL-10 gene therapy by usinglong-term allograft acceptance [5].
Although allo-MHC is the main target for alloimmune different vectors (such as, naked plasmid DNA, retrovi-
ral, herpes simplex viral and adenoviral vector or lipidresponse, exposure of these donor MHC antigens through
the thymus or hematopoietic stem cells could serve as a mediated) significantly prolonged murine and rabbit car-
diac allograft survival [16–19]. In addition, TGF- genestrategy for inducing antigen-specific tolerance [6]. The
involution of the adult thymus makes the thymic ap- therapy was shown to prolong the murine cardiac and
liver allograft survival [16, 20, 21]. Along with the immu-proach not feasible for human gene therapy. However,
DNA-mediated gene transfer of MHC classes I and II nosuppressive properties of TGF-, it induces fibrosis
and may play a role in chronic rejection. This issue hasmolecules to recipient bone marrow cells prolonged sur-
vival of murine cardiac allografts [7]. By using a similar not been addressed in these studies. One recent study
investigated the effects of IL-4 gene therapy by usingapproach, it was shown that pretransplant administration
of a single donor class I MHC molecule was sufficient for recombinant adenovirus vector in rat heart transplanta-
tion model. Although IL-10 gene therapy significantlythe indefinite survival of cardiac allografts [8]. Retroviral
transduction of bone marrow with the donor MHC gene prolonged the cardiac allograft survival, IL-4 gene ther-
apy had no effect [22].significantly prolonged murine skin allograft survival and
miniature swine kidney allograft survival [9, 10]. A recent Chemokines are members of a family of small, in-
ducible, and secreted proteins that are produced in in-study, using liposomes to transfect cultured recipient
hepatocytes with plasmid DNA encoding the soluble flammation and regulate leukocyte and lymphocyte re-
cruitment. Increasing number studies have shown thatdonor MHC class I Ag, abrogated HAR and prolonged
allograft survival in presensitized rat cardiac allograft chemokines play an important role in allograft rejection
[23]. vMIP-II and MC148 are two recently identifiedmodel [11]. These studies demonstrate that the applica-
tion of gene therapy of donor MHC molecules through chemokine homologues encoded by human herpes virus
8 and molluscum contagiosum that have antagonisticbone marrow cells provides a new strategy for inducing
transplantation tolerance. activities against multiple different CC and CXC chemo-
kine receptors. Plasmid-mediated gene transfer of eitherSystemic administration of CTLA4Ig and anti-CD40
ligand has been tested in numerous allograft and xeno- chemokine antagonists markedly prolonged vascularized
and nonvascularized cardiac allograft survival in micegraft models, and it has been shown in some studies that
they significantly prolong survival and induce antigen- [24]. This approach resulted in a marked decrease of
donor-specific cytotoxic T lymphocytes infiltrating thespecific tolerance [5]. The effect of local expression of
CTLA4Ig has been studied by using replication-defec- grafts and inhibited alloantibody production. Targeting
the chemokine functions by gene therapy can be anothertive adenoviral vector in cold-preserved murine liver al-
lograft model. This method induced indefinite survival novel approach for inhibition of alloimmune response.
Following the activation of effector mechanisms, allo-of the recipient with donor-specific unresponsiveness
[12]. Ex vivo perfusion of the donor hearts with recombi- immune responses need to be down-regulated. This is
carried out by several mechanisms that inhibit T cells atnant adenovirus encoding CTLA4Ig cDNA induced in-
definite graft survival in rat cardiac allotransplantation the later stages of the alloimmune response. CTLA4
molecules expressed on activated T cells interact with[13]. Transplantation of allogenic mouse islets expressing
the human CTLA4Ig cDNA following gene gun delivery B7 molecules on APCs and deliver inhibitory signals
to T cells. The Fas/Fas ligand (FasL) system plays analso prolonged allograft survival significantly [14]. Gene
transfer of anti-CD40 ligand has not yet been studied. important role in the induction of lymphoid apoptosis
and can turn off immune responses. Two immune-privi-The role of cytokines in the induction of allograft ac-
ceptance and transplantation tolerance has been largely leged sites, the eye and the testis, constitutively express
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FasL and protect cells from immune destruction. Gene prevent antibody-induced transplant arteriosclerosis in
mouse cardiac allografts [32].therapy, using FasL, has been studied by several groups
Endothelium-derived nitric oxide is an endogenousin different transplantation models, but the results are
inhibitor of vascular lesion formation. Gene transfer ofcontroversial. Gene transfer of murine FasL by replica-
endothelial cell nitric oxide synthase by the Sendai virus/tion defective adenovirus significantly prolonged rat re-
liposome in vivo gene transfer technique to the endothe-nal allograft survival [25]. Similar results were obtained
lium of rat carotid arteries significantly decreased thein the rat liver transplantation model by using rat pFasL
balloon injury-induced damage and neointima formationconjugated to liposome vesicles (hemagglutinating virus
[33]. Adenoviral-mediated inducible nitric oxide syn-of Japan liposome) [26]. However, heart allografts from
thase gene transfer completely suppressed the develop-FasL transgenic mice were more rapidly rejected than
ment of arteriosclerosis in both untreated or cyclosporinenontransgenic control allografts [27].
A-treated rat aortic allografts [34].A recent interesting study demonstrated the impor-
Intercellular adhesion molecule-1 (ICAM-1) is antance of secondary lymphoid tissue in alloimmune re-
important mediator of cell adhesion and T-cell costimu-sponse. In this study, cardiac allografts were accepted in-
lation. The use of ex vivo hyperbaric transfection of anti-definitely in recipient mice that lack secondary lymphoid
sense oligodeoxynucleotides that blocked ICAM-1 re-tissue, indicating that the alloimmune response to a vas-
sulted in the reduction of chronic graft vascular diseasecularized organ cannot be initiated in the graft itself and
and reperfusion injury in rat cardiac allografts [35, 36].requires the presence of secondary lymphoid tissue [28].
Cyclin-dependent kinase 2 is an important enzyme inThis study may challenge the idea of using gene therapy
the transition from the G1-S phase of the cell cycle andmethods locally at the transplanted organ and may sug-
mediates smooth muscle cell proliferation. The use of genegest that secondary lymphoid organs could be potential
transfer of antisense phosphorothioate oligodeoxynucle-targets. Dendritic cells are highly specialized APCs that
otide against this enzyme inhibited intimal hyperplasiainitiate and modulate immune responses and play an
and expression of vascular cell adhesion molecule-1 [37].essential role in T-cell activation and central and periph-
eral tolerance. A recent study used dendritic cells for
XENOTRANSPLANTATIONadenoviral delivery of CTLA4Ig and induced alloanti-
gen-specific T-cell hyporesponsiveness [29]. Organ shortage is one of the major limitations in trans-
plantation, and this has stimulated a great deal of re-
search into the possibility of using nonhuman donors forMODULATION OF NONIMMUNOLOGIC
transplantation. The preferred donor animal species forCAUSES OF GRAFT LOSS
xenotransplantation is the pig. The initial barrier to xeno-
Ischemia-reperfusion injury is an important cause of transplantation is hyperacute rejection (HAR), which
early nonimmune loss of the allograft. It induces the results in the loss of graft within a few minutes to hours
formation of reactive oxygen species by endothelial dam- because of antibody-mediated complement activation of
age, which may cause cell death within the graft or may the graft endothelium. This xenoreactive natural anti-
induce acute or chronic rejection by activating cytokines body predominantly recognizes the unique carbohydrate
and adhesion molecules and recruiting leukocytes. This structure, Gal1-3Gal, which is found as the terminal
subject has also been of interest in gene therapy. Mito- sugar on glycolipids and glycoproteins present on the
chondrial superoxide dismutase gene was transferred to donor pig endothelium. Humans do not express this anti-
the mouse liver prior to the lobar ischemia-reperfusion gen and have antibody to this antigen, in a similar fashion
injury. It was shown to reduce acute liver damage signifi- to blood group antigens. This epitope is synthesized by
cantly by inhibiting the redox-mediated activation of nu- an enzyme called -galactosyltransferase. It was shown
clear factor-B and activator protein-1, which are the that introducing a functioning gene that encodes this
immediate early transcription factors that represent com- enzyme by retroviral gene transfer into autologous bone
mon pathways by which cells respond to environmental marrow cells overcame the HAR in a mouse model [38].
stress [30]. The effector mechanism of HAR is the activation of com-
Apoptosis plays an important role in organ preserva- plement cascade. There are complement-regulatory pro-
tion and rejection. Overexpression of antiapoptotic genes teins (CRPs) present on the donor endothelium that
in the allograft may prevent ischemia/reperfusion-induced regulate the activation of complement. These proteins
apoptosis. Bcl-2 gene transfer to the mouse liver by re- include decay-accelerating factor (DAF;CD55), mem-
combinant adenovirus before procurement significantly brane cofactor protein (MCP;CD46), and CD59. Xeno-
decreased hepatocyte injury and the number of apoptotic graft endothelium is severely damaged because of a lack
cells [31]. It was also demonstrated that the expression of these CRPs. Transgenic pigs that express human CRPs
have been developed to limit complement-induced dam-of genes that encode heme oxygenase-1, bcl-xl, and A20
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9. Sykes M, Sachs DH, Nienhuis AW, et al: Specific prolongationage. Heart and kidneys derived from transgenic pigs that
of skin graft survival following retroviral transduction of bone
express DAF did not develop HAR if transplanted into marrow with an allogenic major histocompatibilty complex gene.
Transplantation 55:197–202, 1993nonhuman primates [39–42]. Furthermore, the use of
10. Emery DW, Sablinski T, Shimada H, et al: Expression of an alloge-transgenic pigs that express DAF with CD46 or CD59 as
nic MHC DRB transgene, through retroviral transduction of bone
donors for kidney or heart transplantation into baboons marrow, induces specific reduction of alloreactivity. Transplanta-
tion 27:1414–1423, 1997show to prolong graft survival without immunopatholog-
11. Geissler EK, Graeb C, Tange S, et al: Effective use of donorical findings of HAR [43].
MHC class I gene therapy in organ transplantation: Prevention of
If HAR can be avoided, the xenograft is subject to antibody-mediated hyperacute heart allograft rejection in highly
sensitized rat recipients. Hum Gene Ther 11:459–469, 2000acute vascular rejection (delayed xenograft rejection)
12. Olthoff KM, Judge TA, Gelman AE, et al: Adenovirus-mediatedwithin a few days to weeks post-transplantation, which
gene transfer into cold-preserved liver allografts: Survival pattern
is probably T-cell independent and is caused by antibod- and unresponsiveness following transduction with CTLA4Ig. Nat
Med 4:194–200, 1998ies, macrophages, cytokines, and chemokines. If these
13. Yang Z, Rostami S, Koeberlein B, et al: Cardiac allograft toler-problems are overcome, which is very difficult, a third
ance induced by intra-arterial infusion of recombinant adenoviral
hurdle to the final success of the xenotransplantation is CTLA4Ig. Transplantation 67:1517–1523, 1999
14. Gainer AL, Suarez-Pinzon WL, Min WP, et al: Improved sur-T-cell-mediated rejection. Similar approaches as in al-
vival of biolistically transfected mouse islet allografts expressinglotransplantation (using CTLA4Ig, IL-10, TGF- gene
CTLA4Ig or soluble fas ligand. Transplantation 66:194–199, 1998
transfer) can be used in xenotransplantation to prevent 15. Sayegh MH, Akalin E, Hancock WW, et al: CD28–B7 blockade
after alloantigen challenge in vivo inhibits Th1 cytokines but sparesT-cell-mediated rejection.
Th2. J Exp Med 181:1869–1874, 1995
16. Qin L, Chavin KD, Ding Y, et al: Multiple vectors effectively
achieve gene transfer in a murine cardiac transplantation model:CONCLUSION
Immunosuppression with TGF1 or vIL-10. Transplantation 59:
809–816, 1995Gene therapy, which is in the early stages of develop-
17. Qin L, Chavin KD, Ding Y, et al: Retrovirus-mediated transferment, holds great promise for allotransplantation and
of viral IL-10 gene prolongs murine cardiac allograft survival.
xenotransplantation. Improvements in transfer vectors J Immunol 156:2316–2323, 1996
18. Brauner R, Nonoyama M, Laks H, et al: Intracoronary adeno-and delivery protocols to obtain efficient transfection
virus-mediated transfer of immunosuppressive cytokine geneswith minimal toxicity, along with a better understanding prolongs allograft survival. J Thorac Cardiovasc Surg 114:923–
of alloimmune responses to identify the most efficient 933, 1997
19. DeBruyne LA, Li K, Chan SY, et al: Lipid-mediated gene transfergene or gene combinations, would make gene therapy
of viral IL-10 prolongs vascularized cardiac allograft survival byan important field of transplantation in this century. inhibiting donor-specific cellular and humoral immune responses.
Gene Ther 5:1079–1087, 1998
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